Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BMS 986012

Drug Profile

BMS 986012

Alternative Names: Anti-fucosyl-GM1 - Bristol-Myers Squibb; BMS986012

Latest Information Update: 28 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bristol-Myers Squibb
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Fucosyl GM1 ganglioside inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Small cell lung cancer

Most Recent Events

  • 28 Oct 2019 No recent reports of development identified for phase-I development in Small-cell-lung-cancer(Monotherapy) in Japan (IV, Liquid)
  • 08 Sep 2017 Initial efficacy and adverse events data from a phase I/II trial in Small cell lung cancer (Combination therapy, Second line therapy) presented at the 42nd European Society for Medical Oncology Congress (ESMO-2017)
  • 29 Aug 2017 Bristol-Myers Squibb completes a phase I trial in Small cell lung cancer (Monotherapy) in Japan (IV) (NCT02949895)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top